The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{8cf4899b294a4aa8b3a45f5dfd651dbc,
title = "The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.",
abstract = "WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of ",
author = "Nicola Edwards and Richard Steeds and Colin Chue and Paul Stewart and Charles Ferro and Jonathan Townend",
year = "2011",
month = sep,
day = "28",
doi = "10.1111/j.1365-2125.2011.04102.x",
language = "English",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - The Safety and Tolerability of Spironolactone in Patients with Mild-Moderate Chronic Kidney Disease.

AU - Edwards, Nicola

AU - Steeds, Richard

AU - Chue, Colin

AU - Stewart, Paul

AU - Ferro, Charles

AU - Townend, Jonathan

PY - 2011/9/28

Y1 - 2011/9/28

N2 - WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of

AB - WHAT THIS PAPER ADDS What is already known about this subject Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction. What this study adds. Non-diabetic patients with early stage CKD on concomitant with ACE inhibition or angiotensin II receptor blockade with a serum potassium of

U2 - 10.1111/j.1365-2125.2011.04102.x

DO - 10.1111/j.1365-2125.2011.04102.x

M3 - Article

C2 - 21950312

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -